Goldman Sachs’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Goldman Sachs’s Portfolio KBIO Stock Details KBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,807	Closed	-$7K	–	7821
2015 Q2	$7K	Buy	1,807 +120	+7%	+$509	﹤0.01%	7183
2015 Q1	$7K	Sell	1,687 -15	-0.9%	-$67	﹤0.01%	6998
2014 Q4	$24K	Buy	1,702 +66	+4%	+$942	﹤0.01%	6962
2014 Q3	$20K	Sell	1,636 -528	-24%	-$7.28K	﹤0.01%	6991
2014 Q2	$39K	Buy	+2,164	New	+$37K	﹤0.01%	6799
2013 Q4	–	Sell	-7,127	Closed	-$258K	–	7056
2013 Q3	$258K	Buy	+7,127	New	+$325K	﹤0.01%	5680

Other funds holding KBIO

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Goldman Sachs's KBIO Position: Q3 2015 in Review

Goldman Sachs sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q3 2015, closing a stake of 1,807 shares — an estimated $7K sold.

Goldman Sachs first reported a position in KBIO in Q3 2013 and held it in 6 quarters. The position peaked at $258K in Q3 2013. 14 funds tracked by Wall St. Rank hold KBIO as of Q3 2015.

Goldman Sachs reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q3 2015 after selling out during the quarter.
Goldman Sachs sold 1,807 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q3 2015, an estimated $7K.
Goldman Sachs first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q3 2013 and held it in 6 quarters.
Goldman Sachs's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $258K in Q3 2013.
14 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q3 2015.

Based on Goldman Sachs's 13F filing for Q3 2015, filed 13 Nov 2015.